重组人内皮抑素联合顺铂化疗治疗恶性黑色素瘤的临床疗效及对MVD、VEGF水平的影响

Clinical Therapeutic Effect of Recombinant Human Endostatin Combined with Cisplatin Chemotherapy in the Treatment of Malignant Melanoma and Its Influence on MVD and VEGF

目的:探讨重组人内皮抑素联合顺铂化疗治疗恶性黑色素瘤的临床疗效及对恶性黑色素瘤微血管密度(MVD)和内皮生长因子(VEGF)水平的影响。方法:按照随机数字表法将2008年3月-2015年3月我院收治的恶性黑色素瘤患者分为两组,对照组予以30 mg/m2的顺铂化疗,观察组在对照组基础上静脉滴注重组人内皮抑素15mg/d,治疗2个周期后比较两组的临床疗效和对MVD、VEGF计数的影响。结果:观察组临床疗效优于对照组,差异有统计学意义(Z=-2.673,P=0.008)。治疗后两组MVD、VEGF计数较治疗前均下降,且观察组下降更明显,差异均有统计学意义(t=3.759,4.082;P<0.05)。两组不良反应发生率差异无显著性(P>0.05)。结论:重组人内皮抑素联合顺铂化疗治疗恶心黑色素瘤能明显提高临床治疗效果,抑制恶性黑色素瘤组织中的MVD和VEGF表达。

Objective To explore the clinical effect of recombinant human endostatin combined with cisplatin chemotherapy for malignant melanoma and its influence on microvessel density（ MVD） and vascular endithelial growth factor（ VEGF） of malignant melanoma.Methods The patients with malignant melanoma in our hospital from March 2008 to March 2015 were divided into two groups according to random number table method,the control group were given cisplatin chemotherapy with30 mg/m2 and the observation group based on the cisplatin chemotherapy treatment of control group were treated by 15 mg/d intravenous infusion of recombinant human endostatin. The clinical effect and influences on MVD and VEGF were compared between two groups after treating for two cycles.Results The clinical effect of observation group was better than that of control group（ Z =-2.673,P〈0.05）.MVD count and VEGF count of two groups after treatment were decreased than those of before treatment and compared with control group MVD and VEGF count in observation group decreased significantly.There was no significant difference of adverse reactions in two groups（ P〉0.05）.Conclusion Recombinant human endostatin combined with cisplatin chemotherapy in the treatment of malignant melanoma can significantly improve the clinical effect and inhibit the expression of MVD and VEGF of malignant melanoma.